Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Completed 16Active not recruiting 14Recruiting 11Withdrawn 4Terminated 4Unknown 3Not yet recruiting 3

Sponsor Class

OTHER 2FED 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Prostatic Neoplasms 3Neoplasm Metastasis 1

Interventions

Carboplatin 79Cisplatin 74Bevacizumab 62Radiotherapy 59Drug Therapy 57Capecitabine 57Oxaliplatin 56tislelizumab 54toripalimab 45Paclitaxel 44Gemcitabine 43pembrolizumab 40anlotinib 40Specimen Handling 39sintilimab 37Cyclophosphamide 34130-nm albumin-bound paclitaxel 34Injections 30Pemetrexed 28camrelizumab 26Surgical Procedures, Operative 26Magnetic Resonance Spectroscopy 25lenvatinib 24apatinib 23Docetaxel 23Etoposide 22S 1 (combination) 21Fluorouracil 21Immune Checkpoint Inhibitors 20Biopsy 20

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2 × Not yet recruiting × apalutamide × Clear all
NCT05778097 2023-03-21

ARES

The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School

Phase 2 Not yet recruiting
103 enrolled
Genitourinary

Prostatic Neoplasms

NCT05717582 2023-02-08

CHAMPION

Fudan University

Phase 2 Not yet recruiting
47 enrolled
Genitourinary

Prostatic Neoplasms

NCT05422911 2022-06-21

Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

James J. Peters Veterans Affairs Medical Center

Phase 2 Not yet recruiting
200 enrolled
Genitourinary

Neoplasm Metastasis, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡